Organogenesis Holdings Inc. (ORGO) Stock Price & How to Invest
Last updated July 2026
Short answer
You can invest in Organogenesis (ORGO) by buying shares or fractional shares at any major US broker, through a small-cap healthcare or medical-device ETF that happens to hold it, or as one holding in a thematic basket. Organogenesis is a regenerative medicine company focused on advanced wound care and surgical and sports medicine, selling products like Apligraf, PuraPly, Affinity, and ReNu that help the body heal chronic wounds and soft tissue. The single most important thing to understand is that the thesis is dominated by Medicare reimbursement policy: a large share of revenue comes from skin substitutes billed to Medicare, so changes in how CMS pays for those products can swing sales dramatically. It is a small-cap, reimbursement-driven healthcare stock, not a steady compounder.
ORGO stock price
As of 2026-07-14, Organogenesis Holdings Inc. (ORGO) last closed at $2.33, down 48.1% over the past year. Over the past 52 weeks it has traded between $2.24 and $6.54.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Organogenesis Holdings Inc.'s investor relations page. Walnut is informational, not investment advice.
What does Organogenesis Holdings Inc. (ORGO) do?
Organogenesis Holdings Inc. is a regenerative medicine company that develops, manufactures, and commercializes products for the advanced wound care and surgical and sports medicine markets. Its advanced wound care line includes bioengineered and tissue-based products such as Apligraf, a bi-layered skin substitute for venous leg ulcers and diabetic foot ulcers; PuraPly and PuraPly AM, an antimicrobial wound matrix; and Affinity, a fresh human placental allograft. Its surgical and sports medicine products include ReNu, a cryopreserved amniotic suspension allograft, and NuCel. The company became publicly traded in 2018 through a SPAC merger with Avista Healthcare Public Acquisition Corp. and trades on the Nasdaq under the ticker ORGO. Because a large portion of its wound care revenue is billed to Medicare, the business is unusually sensitive to how the Centers for Medicare and Medicaid Services chooses to pay for skin substitutes.
That sensitivity is the central story in 2026. CMS finalized major payment reform for skin substitutes and cellular and tissue-based products under the CY 2026 fee schedule, moving toward a per-square-centimeter payment methodology, and the transition has sharply disrupted the market. Organogenesis reported a steep revenue decline in early 2026, with advanced wound care sales down substantially year over year, and guided full-year 2026 revenue well below its record 2025 result, citing reimbursement and coverage changes plus market confusion over wastage. Management has framed 2026 as a transition year, expecting the market to adapt over the course of the year and pointing to a return toward more normalized growth in 2027. At the same time, the company is pursuing a Biologics License Application for ReNu in symptomatic knee osteoarthritis pain, a much larger addressable market, though the two supporting Phase 3 trials produced mixed results. As a small-cap, the stock traded at just a few dollars per share in mid-2026 and carries the volatility typical of a company in the middle of a policy-driven reset.
What's driving Organogenesis Holdings Inc. (ORGO)?
1. CMS reimbursement reset and market adaptation
The finalized CY 2026 CMS payment reform for skin substitutes is the dominant near-term variable. The shift toward a per-square-centimeter methodology and coverage changes drove a sharp drop in advanced wound care revenue in early 2026. Management publicly commended aspects of the reform and expects the market to adapt through the year, so how quickly clinicians and payers settle into the new rules is the swing factor for whether sales stabilize.
2. ReNu BLA in knee osteoarthritis
Organogenesis is pursuing a Biologics License Application for ReNu, a cryopreserved amniotic suspension allograft, for symptomatic knee osteoarthritis pain, a far larger market than wound care. The FDA accepted the BLA for review, supported by RMAT designation and two Phase 3 trials, though one study met its primary endpoint while the second missed it. Approval would be a step-function expansion of the addressable market, but the mixed data adds meaningful regulatory uncertainty.
3. Product breadth and installed clinician base
The company sells a portfolio spanning advanced wound care and surgical and sports medicine, with long commercial histories for products like Apligraf and PuraPly and relationships across wound care clinics, hospitals, and physician offices. That breadth and installed base give it multiple revenue lines and a platform to reintroduce products under the new reimbursement framework, which management argues positions it to recover share once the market normalizes.
4. Capital position and Avista backing
In 2025 Organogenesis raised capital through a private placement of Series A convertible preferred stock with Avista, its long-time backer, strengthening the balance sheet ahead of the reimbursement transition. Access to capital matters for a company absorbing a steep revenue decline while funding manufacturing capacity and the ReNu program. How management balances cash, investment, and the preferred stock terms is important to whether it can fund its way through the transition year.
What are the risks to Organogenesis Holdings Inc. (ORGO)?
The dominant risk is Medicare reimbursement policy: a large share of revenue depends on how CMS pays for skin substitutes, and the CY 2026 payment reform already drove a sharp advanced wound care revenue decline and a large cut to full-year guidance versus 2025. Further coverage tightening, local coverage determinations, or continued market confusion over wastage could prolong the downturn or make recovery slower than management expects. The ReNu BLA carries regulatory risk because one of the two Phase 3 studies missed its primary endpoint, so approval and any eventual commercial ramp are far from guaranteed. As a small-cap in the middle of a business reset, ORGO is thinly valued, can be volatile, and faces execution risk on manufacturing, cost control, and cash. The Avista preferred stock and liquidation-preference terms add potential dilution and change-of-control considerations for common shareholders.
How is Organogenesis Holdings Inc. (ORGO) valued? (approximate, Jul 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Organogenesis Holdings Inc.'s investor relations page or your broker.
- Revenue trajectory: Guided full-year 2026 net revenue sharply below record 2025, reflecting a projected double-digit percentage decline driven by CMS reimbursement and coverage changes
- Advanced wound care: Reported a steep year-over-year decline in early 2026, the segment most exposed to the skin-substitute payment reform
- Profitability: Under pressure during the 2026 transition as revenue contracts faster than the cost base; management frames 2026 as a reset year with recovery targeted for 2027
- Market cap: Small-cap; the stock traded at only a few dollars per share in mid-2026, so market value is modest relative to its former highs
- Balance sheet: Bolstered in 2025 by a Series A convertible preferred private placement with Avista; capital position is a key watch item during the revenue decline
- Valuation lens: Trades more as a policy-and-pipeline story than on current earnings; conventional multiples are distorted by the 2026 reset
Figures here are qualitative and tied to the asOf date; verify live numbers in the latest filings before acting. Because 2026 is a reimbursement-driven transition year with sharply lower guidance, trailing and forward earnings multiples are unreliable, and the stock's value hinges more on whether the wound care market normalizes and whether ReNu is approved than on any single quarter's results. Do not treat any of this as a price target or a recommendation.
Who competes with Organogenesis Holdings Inc. (ORGO)?
Skin substitute and advanced wound care specialists
Organogenesis competes directly with other makers of cellular, tissue-based, and bioengineered wound products, including MiMedx and Integra LifeSciences, along with smaller allograft and amniotic-tissue suppliers. These rivals face the same CMS reimbursement reset, so the competitive picture in 2026 is shaped as much by shared policy headwinds as by product differentiation.
Large diversified wound care and med-tech players
Bigger diversified companies such as Smith and Nephew, 3M's health care spinoff Solventum, and Convatec offer broad wound care portfolios and negative-pressure and dressing technologies. They compete for the same clinicians and hospital contracts with more scale, distribution reach, and financial resources than a small-cap like Organogenesis.
Surgical, sports medicine, and orthobiologics
In surgical and sports medicine, and in the potential ReNu knee osteoarthritis market, Organogenesis would compete with orthobiologics and injectable-therapy providers and larger orthopedics companies. This is a different, larger arena where established players have entrenched relationships, making commercial execution a key differentiator if ReNu reaches the market.
How to invest in Organogenesis Holdings Inc. (ORGO)
There are three common ways to get ORGO exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so ORGO sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where ORGO fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Organogenesis Holdings Inc. (ORGO)
Organogenesis is a small-cap regenerative medicine company whose near-term results are being reshaped by 2026 CMS reimbursement changes for skin substitutes, offset by a potential longer-term catalyst in the ReNu knee osteoarthritis program. The question is how much reimbursement and execution risk fits your portfolio, not whether the science is real.
Build a basket around ORGO with Walnut
Use Organogenesis Holdings Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is ORGO a good stock to buy right now?
+
That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is that 2026 is a transition year, the CMS reimbursement market eventually normalizes, and the ReNu knee osteoarthritis program opens a much larger market. The bear case is that a large share of revenue hinges on Medicare payment policy that just cut sharply, guidance fell steeply, and the ReNu Phase 3 data were mixed. Weigh both against your portfolio and consider that small-caps in a reset can be volatile.
What does Organogenesis actually do?
+
Organogenesis is a regenerative medicine company that makes products to help the body heal. Its advanced wound care line includes skin substitutes and tissue-based products like Apligraf, PuraPly, and Affinity for chronic wounds such as diabetic foot ulcers and venous leg ulcers. Its surgical and sports medicine line includes ReNu and NuCel for soft-tissue healing. It sells to wound care clinics, hospitals, and physicians rather than directly to consumers.
Why did Organogenesis revenue drop in 2026?
+
The main driver was CMS reimbursement and coverage changes for skin substitutes under the CY 2026 fee schedule, which moved toward a per-square-centimeter payment method and created confusion in the market. Because much of Organogenesis's advanced wound care revenue is billed to Medicare, the policy shift disproportionately hit that segment, and the company guided full-year 2026 revenue well below its record 2025 result.
How does Medicare reimbursement affect ORGO?
+
A large portion of Organogenesis's wound care products are used in Medicare patients, so how CMS chooses to pay for skin substitutes directly shapes demand and pricing. When CMS changes payment methodology, coverage rules, or local coverage determinations, it can rapidly raise or lower how much providers are reimbursed for using these products, which flows straight through to Organogenesis's sales. That makes reimbursement policy the single biggest external variable for the stock.
What is ReNu and why does it matter?
+
ReNu is a cryopreserved amniotic suspension allograft that Organogenesis is developing for symptomatic knee osteoarthritis pain. It matters because knee osteoarthritis is a far larger market than wound care, so approval could meaningfully expand the company's opportunity. The FDA accepted a Biologics License Application for review, supported by RMAT designation, but the two supporting Phase 3 trials had mixed results, so the outcome is uncertain.
Is Organogenesis still publicly traded?
+
Yes. As of mid-2026, Organogenesis Holdings trades on the Nasdaq under the ticker ORGO. It became public in 2018 through a SPAC merger with Avista Healthcare Public Acquisition Corp. In 2025 it raised capital through a Series A convertible preferred placement with Avista, but that was a financing, not a take-private transaction, and the common stock continues to trade.
Does Organogenesis pay a dividend?
+
Organogenesis has not been known as a dividend payer; as a small-cap regenerative medicine company it has generally reinvested in its business, manufacturing, and clinical programs rather than returning cash to shareholders. Investors typically hold it for potential recovery and pipeline upside rather than income. Always check the latest company disclosures before assuming anything about capital returns.
How can I get exposure to ORGO through an ETF?
+
ORGO can appear in broad small-cap, healthcare, or medical-device ETFs, though as a small company its weighting in any diversified fund tends to be tiny. ETF exposure spreads single-stock risk across many holdings but dilutes how much an ORGO move affects you. Always check a fund's holdings and weighting before assuming meaningful exposure to Organogenesis specifically.
What are the main risks of investing in ORGO?
+
The central risk is Medicare reimbursement policy, which just drove a steep revenue decline and a large cut to 2026 guidance and could tighten further. On top of that, the ReNu BLA carries regulatory risk because one Phase 3 study missed its primary endpoint, the company is a volatile small-cap absorbing a business reset, and the Avista preferred stock adds potential dilution. Execution on cost, cash, and market recovery all matter, and none of it is guaranteed.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Organogenesis Holdings Inc.'s investor relations page or your broker before making investment decisions.